TAMPERE,
Finland, June 19, 2024 /PRNewswire/ -- Bioretec
Ltd., a pioneer in biodegradable orthopedic implants, is
pleased to announce that a number of cases have been performed
around the U.S. utilizing the RemeOs™ technology. The follow-up
results confirmed successful implantation and fracture healing were
achieved in all cases. Surgeons reported very positive feedback in
that there is no change to existing surgical technique while
operating with an absorbable metal implant for their patients. The
added benefit of osteopromotion and bioactivity on the fracture
healing site was also reported to be a factor in the surgeon's
choice to use RemeOs™ screws in these procedures.
"The controlled launch of the RemeOs™ trauma screw in
the United States has progressed
very much in line with our expectations. In my short tenure with
Bioretec, these excellent results and surgeon feedback have given
me confidence in our plans to increase our commercialization
efforts in the U.S.", says Alan Donze, CEO of
Bioretec.
Further enquiries
Alan Donze, CEO, tel. +358 40 663 5011
Johanna Salko, CFO,
tel. +358 40 754 8172
Bioretec in brief
Bioretec is a globally operating Finnish medical device company
that continues to pioneer the application of biodegradable
orthopedic implants. The company has built unique competencies in
the biological interface of active implants to enhance bone growth
and accelerate fracture healing after orthopedic surgery. The
products developed and manufactured by Bioretec are used worldwide
in approximately 40 countries.
Bioretec is developing the new RemeOs™ product line based on a
magnesium alloy and hybrid composite, introducing a new generation
of strong biodegradable materials for enhanced surgical outcomes.
The RemeOs™ implants are absorbed and replaced by bone, which
eliminates the need for removal surgery while facilitating fracture
healing. The combination has the potential to make titanium
implants redundant and help clinics reach their Value-Based
Healthcare targets while focusing on value for patients through
efficient healthcare. The first RemeOs™ product market
authorization has been received in the U.S. in March 2023, and in Europe, the CE-mark is expected to be received
during the second quarter of 2024. Bioretec is positioning itself
to enter the addressable USD 7
billion global orthopedic trauma market and become a game
changer in surgical bone fracture treatment.
Better healing – Better life. www.bioretec.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioretec/r/bioretec-reports-successful-clinical-outcomes-from-u-s--controlled-launch-of-remeos--trauma-screw--f,c4004302
View original
content:https://www.prnewswire.com/news-releases/bioretec-reports-successful-clinical-outcomes-from-us-controlled-launch-of-remeos-trauma-screw-fracture-healing-confirmed-in-100-of-surgical-procedures-302177168.html
SOURCE Bioretec